Eupraxia Pharmaceuticals Inc. (TSX: EPRX, NASDAQ: EPRX) is quietly assembling the kind of boardroom roster that makes Wall Street’s biotech specialists sit up, sharpen their models, and wonder if this “diffusion‑obsessed” Canadian upstart is planning something much bigger than a Phase 2 read‑out.
A…